Premium
Phosphodiesterase‐5 Inhibition with Tadalafil Attenuates Left Ventricular Dysfunction and Cardiomyocyte Apoptosis in Doxorubicin‐induced Cardiotoxicity in Mice
Author(s) -
Koka Saisudha,
Das Anindita,
Zhu ShuGuang,
Durrant David,
Xi Lei,
Kukreja Rakesh C
Publication year - 2010
Publication title -
the faseb journal
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.709
H-Index - 277
eISSN - 1530-6860
pISSN - 0892-6638
DOI - 10.1096/fasebj.24.1_supplement.785.10
Subject(s) - cardiotoxicity , doxorubicin , tadalafil , tunel assay , apoptosis , pharmacology , dexrazoxane , medicine , cgmp specific phosphodiesterase type 5 , chemistry , chemotherapy , cancer , sildenafil , anthracycline , biochemistry , breast cancer
Doxorubicin (DOX) is one of the most effective anticancer drugs. However, its cardiotoxicity remains a major clinical concern. As phosphodiesterase‐5 (PDE5) inhibitors are cardioprotective, we hypothesized that tadalafil (TAD), a long acting PDE5 inhibitor, would provide protection against DOX‐induced cardiotoxicity. CF‐1 mice received Saline (0.2 ml ip), DOX (15 mg/kg ip) or DOX+TAD (4 mg/kg po for 9 days; n=18–24/group). Left ventricular (LV) function was assessed by echocardiography and Millar catheter. DOX‐mediated impairment of LV function was significantly reduced by TAD+DOX (p<0.05). Western Blots revealed that DOX‐mediated reduction of Bcl‐2 and GATA‐4 were maintained by TAD+DOX. Antioxidant capacity was also improved through enhanced MnSOD in TAD+DOX. Immunofluorescence staining of Desmin and TUNEL assay showed that DOX‐induced myofibrillar disarray and apoptosis were attenuated by TAD. TAD+DOX significantly increased cGMP level and PKG activity in heart as compared to DOX. Co‐treatment of TAD with DOX did not interfere with the anti‐cancer efficacy of DOX, as determined by human osteosarcoma (OSA‐1) cell viability assay and tumor xenograft model. In conclusion, TAD improved LV function and prevented cardiomyocyte apoptosis via upregulation of cGMP, PKG and MnSOD, without interfering with the chemotherapeutic benefits of DOX. (Supported by NIH HL51045, HL79424, HL93685 & AHA 0765273U)